<?xml version="1.0" encoding="UTF-8"?>
<p>Direct acting antiviral (DAA) regimens have radically changed the treatment of hepatitis C virus (HCV) infection. Introduced in 2014, these highly effective regimens are orally administered and, compared to earlier options, provide a shorter and more easily tolerated course of treatment. DAAs have changed the landscape of HCV treatment by expanding the scope of care to a wider range of patient populations, including people who inject drugs (PWID) [
 <xref rid="B1-ijerph-17-04951" ref-type="bibr">1</xref>].
</p>
